Association of low testosterone with metabolic syndrome and its components in middle-aged Japanese men

Hypertension Research

Volumn 33, Issue 6, 2010, Pages 587-591

  Akishita, Masahiro ^a   Fukai, Shiho ^a   Hashimoto, Masayoshi ^b   Kameyama, Yumi ^a   Nomura, Kazushi ^a   Nakamura, Tetsuro ^c   Ogawa, Sumito ^a   Iijima, Katsuya ^a   Eto, Masato ^a   Ouchi, Yasuyoshi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Research Institute of Aging Science   (Japan)

Author keywords

Androgen; Estrogen; Insulin resistance; Obesity; Sex hormone

Indexed keywords

ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ESTRADIOL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRASTERONE SULFATE; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; ESTRADIOL BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN RESISTANCE; JAPANESE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PREVALENCE; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADIPONECTIN; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BODY MASS INDEX; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; DEHYDROEPIANDROSTERONE SULFATE; DYSLIPIDEMIAS; ESTRADIOL; HUMANS; HYPERTENSION; INSULIN RESISTANCE; JAPAN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PREVALENCE; TESTOSTERONE; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 77953187884     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2010.43     Document Type: Article

References (35)

1. Taskinen MR. Is metabolic syndrome the main threat to human health in the twenty-first century? Arterioscler Thromb Vasc Biol 2007; 27: 2275.
2. Oda E. The metabolic syndrome as a concept of adipose tissue disease. Hypertens Res 2008; 31: 1283-1291.
3. Noda H, Iso H, Saito I, Konishi M, Inoue M, Tsugane S, JPHC Study Group. The impact of the metabolic syndrome and its components on the incidence of ischemic heart disease and stroke: the Japan public health center-based study. Hypertens Res 2009; 32: 289-298.
4. Muller M, den Tonkelaar I, Thijssen JH, Grobbee DE, van der Schouw YT. Endogenous sex hormones in men aged 40-80 years. Eur J Endocrinol 2003; 149: 583-589. (Pubitemid 38054704)
5. Tsai EC, Matsumoto AM, Fujimoto WY, Boyko EJ. Association of bioavailable, free, and total testosterone with insulin resistance: influence of sex hormone-binding globulin and body fat. Diabetes Care 2004; 27: 861-868.
6. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 2000; 23: 490-494.
7. Simon D, Charles MA, Nahoul K, Orssaud G, Kremski J, Hully V, Joubert E, Papoz L, Eschwege E. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: the Telecom Study. J Clin Endocrinol Metab 1997; 82: 682-685.
8. Fogari R, Preti P, Zoppi A, Fogari E, Rinaldi A, Corradi L, Mugellini A. Serum testosterone levels and arterial blood pressure in the elderly. Hypertens Res 2005; 28: 625-630.
9. Khaw K-T, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, Welch A, Day N. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men. Circulation 2007; 116: 2694-2701.
10. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008; 93: 68-75.
11. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Salonen R, Rauramaa R, Salonen JT. Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol 2003; 149: 601-608.
12. Muller M, Grobbee DE, den Tonkelaar I, Lamberts SW, van der Schouw YT. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 2005; 90: 2618-2623. (Pubitemid 40686299)
13. Rodriguez A, Muller DC, Metter EJ, Maggio M, Harman SM, Blackman MR, Andres R. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab 2007; 92: 3568-5372.
14. Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004; 27: 1036-1041.
15. Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006; 91: 843-850.
16. Isobe T, Saitoh S, Takagi S, Takeuchi H, Chiba Y, Katoh N, Shimamoto K. Influence of gender, age and renal function on plasma adiponectin level: the Tanno and Sobetsu study. Eur J Endocrinol 2005; 153: 91-98.
17. Akishita M, Hashimoto M, Ohike Y, Ogawa S, Iijima K, Eto M, Ouchi Y. Low testosterone level is an independent determinant of endothelial dysfunction in men. Hypertens Res 2007; 30: 1029-1034.
18. Akishita M, Hashimoto M, Ohike Y, Ogawa S, Iijima K, Eto M, Ouchi Y. Low testosterone level as a predictor of cardiovascular events in Japanese men with coronary risk factors. Atherosclerosis 2009 (e-pub ahead of print).
19. Fogari R, Preti P, Derosa G, Marasi G, Zoppi A, Rinaldi A, Mugellini A. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur J Clin Pharmacol 2002; 58: 177-180.
20. Matsuzawa Y. Metabolic syndrome\definition and diagnostic criteria in Japan. J Atheroscler Thromb 2005; 12: 301.
21. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome\a new worldwide definition. Lancet 2005; 366: 1059-1062.
22. Takeuchi H, Saitoh S, Takagi S, Ohnishi H, Ohhata J, Isobe T, Shimamoto K. Metabolic syndrome and cardiac disease in Japanese men: applicability of the concept of metabolic syndrome defined by the national cholesterol education program-adult treatment panel III to Japanese men\the Tanno and Sobetsu study. Hypertens Res 2005; 28: 203-208.
23. Nishimura R, Nakagami T, Tominaga M, Yoshiike N, Tajima N. Prevalence of metabolic syndrome and optimal waist circumference cut-off values in Japan. Diabetes Res Clin Pract 2007; 78: 77-84.
24. Rebuffé-Scrive M, Marin P, Björntorp P. Effect of testosterone on abdominal adipose tissue. Int J Obes 1991; 15: 791-795.
25. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, Aleman A, Lock TM, Bosch JL, Grobbee DE, van der Schouw YT. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA 2008; 299: 39-52.
26. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 2005; 63: 280-293.
27. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Valkonen VP, Salonen JT. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab 2005; 90: 712-719.
28. Isidori AM, Caprio M, Strollo F, Moretti C, Frajese G, Isidori A, Fabbri A. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab 1999; 84: 3673-3680.
29. Kalyani RR, Dobs AS. Androgen deficiency, diabetes, and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes 2007; 14: 226-234.
30. Zmuda JM, Cauley JA, Kriska A, Glynn NW, Gutai JP, Kuller LH. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13 year follow-up of former multiple risk factor intervention trial participants. Am J Epidemiol 1997; 146: 609-617.
31. Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R, Miceli M, Mammi C, Piepoli M, Fini M, Rosano GM. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009; 54: 919-927.
32. Laughlin GA, Barrett-Connor E, May S. Sex-specific determinants of serum adiponectin in older adults: the role of endogenous sex hormones. Int J Obes (Lond) 2007; 31: 457-465.
33. Gannagé-Yared MH, Khalife S, Semaan M, Fares F, Jambart S, Halaby G. Serum adiponectin and leptin levels in relation to the metabolic syndrome, androgenic profile and somatotropic axis in healthy non-diabetic elderly men. Eur J Endocrinol 2006; 155: 167-176.
34. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, Matsuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino Y, Funahashi T, Matsuzawa Y. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocytederived protein. Diabetes 2002; 51: 2734-2741.
35. Xu A, Chan KW, Hoo RL, Wang Y, Tan KC, Zhang J, Chen B, Lam MC, Tse C, Cooper GJ, Lam KS. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 2005; 280: 18073-18080.